A phase i dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

Authors
Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2020
This article has no abstract
Epistemonikos ID: edfb14f3137b3a298cdf2aad09c75a56fd290b96
First added on: Feb 12, 2025